Exploring Peptide-Drug Conjugates & Comparing Their Toxicity Profiles With Antibody-Drug Conjugates to Improve Reverse Translation
Time: 2:30 pm
day: Scientific Program Day Two
Details:
- Examining case studies where peptide-drug conjugates have translated toxicity data successfully into the clinic – learn from the successes
- Assessing where we can look to optimize the translation of toxicity data with ADCs by comparing ADCs with PDCs – using a reverse translational approach to minimize toxicities in preclinical studies
- Differentiating the biology of PDCs with ADCs and understanding how models can recapitulate the difference in clinical exposure
